Adial Pharmaceuticals, Inc. (ADIL) Key Metrics
ADIL valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $9.2M
- Enterprise value
- −$16.6M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 3.5
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.50
ADIL key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsADIL valuation Price multiples at each fiscal year-end price.
Price / book−84.9%
0.7
2025 · hover or tap a bar for each year
20162025
Free cash flow yield−139.7 pts
−176.6%
2025 · hover or tap a bar for each year
20162025
ADIL returns How much profit the business earns on the capital it uses.
Return on equity+153.1 pts
−170.7%
2025 · hover or tap a bar for each year
20162025
Return on assets+135.1 pts
−134.7%
2025 · hover or tap a bar for each year
20162025
Asset turnover
0.00
2025 · hover or tap a bar for each year
20162025
ADIL per-share figures Results divided by the shares outstanding at year-end.
Revenue per share
$0.00
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$11.93
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$9.71
2025 · hover or tap a bar for each year
20162025
Book value per share+44.2%
$7.89
2025 · hover or tap a bar for each year
20162025
Shares outstanding−10.1%
669K
2025 · hover or tap a bar for each year
20162025
ADIL financial health Debt, liquidity and how easily interest is covered.
Net debt−$2.1M
−$5.9M
2025 · hover or tap a bar for each year
20162025
Current ratio+6.4%
4.42
2025 · hover or tap a bar for each year
20162025
ADIL efficiency & capital use Working capital cycle and where the cash goes.
Days payables outstanding+178,263 days
292,432 days
2025 · hover or tap a bar for each year
20162025
ADIL valuation history
Fiscal year-endToday10-year median
ADIL returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ADIL debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ADIL cash returned to shareholders
DividendsBuybacksFree cash flow
ADIL price vs earnings per share
Share price at year-endEPS (right axis)
ADIL key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $3.7M | $18.8M | — | — | — | — | — | — | — | — |
| Enterprise value | −$2.2M | $15.0M | — | — | — | — | — | — | — | — |
| Price / book | 0.7 | 4.6 | — | — | — | — | — | — | — | — |
| Earnings yield | −216.9% | −70.3% | — | — | — | — | — | — | — | — |
| Free cash flow yield | −176.6% | −36.9% | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $5.50 | $25.25 | $46.50 | $134.38 | $1,687.50 | $1,062.50 | $1,506.25 | $3,200.00 | — | — |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Earnings per share | −$11.93 | −$17.75 | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$9.71 | −$9.31 | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$9.71 | −$9.31 | — | — | — | — | — | — | — | — |
| Cash per share | $8.80 | $5.04 | — | — | — | — | — | — | — | — |
| Book value per share | $7.89 | $5.47 | — | — | — | — | — | — | — | — |
| Tangible book value per share | $7.89 | $5.47 | — | — | — | — | — | — | — | — |
| Capex per share | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Shares outstanding | 669K | 744K | — | — | — | — | — | — | — | — |
| Change in shares outstanding | −10.1% | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −170.7% | −323.8% | −190.3% | −375.3% | −518.4% | −195.2% | −148.4% | −675.5% | — | — |
| Return on invested capital (ROIC) | — | −831.6% | — | — | — | — | — | — | — | — |
| Return on assets (ROA) | −134.7% | −269.9% | −133.8% | −190.5% | −296.0% | −164.9% | −138.8% | −491.4% | — | −228.5% |
| Return on tangible assets | −117.4% | −261.8% | −147.9% | −232.4% | −263.2% | −198.0% | −112.0% | −247.9% | — | −292.5% |
| Financial health | ||||||||||
| Total debt | — | — | — | $207,375 | $256,960 | — | — | — | $689,265 | $234,255 |
| Cash & short-term investments | $5.9M | $3.8M | $2.8M | $4.0M | $6.1M | $4.4M | $6.8M | $3.9M | $18,248 | $87,993 |
| Net debt | −$5.9M | −$3.8M | −$2.8M | −$3.8M | −$5.8M | −$4.4M | −$6.8M | −$3.9M | $671,017 | $146,262 |
| Debt / equity | — | — | — | 0.06 | 0.07 | — | — | — | — | — |
| Debt / assets | — | — | — | 0.04 | 0.03 | — | — | — | 19.95 | 1.55 |
| Current ratio | 4.42 | 4.16 | 4.90 | 2.67 | 2.37 | 3.41 | 14.24 | 18.19 | 0.03 | 0.55 |
| Quick ratio | 4.42 | 4.16 | 4.90 | 2.67 | 2.37 | 3.41 | 14.24 | 18.19 | 0.03 | 0.55 |
| Interest coverage | — | — | — | -18.6 | -5.3 | — | — | -6.0 | -6.9 | -42.6 |
| Working capital | $4.8M | $3.1M | $2.5M | $3.0M | $3.7M | $3.6M | $7.1M | $4.4M | −$1.0M | −$113,606 |
| Invested capital | −$604,759 | $317,559 | $1.3M | −$517,925 | −$2.3M | −$415,048 | $363,534 | $572,268 | −$326,536 | $42,769 |
| Tangible asset value | $5.3M | $4.1M | $4.1M | $3.0M | $3.3M | $4.0M | $7.1M | $4.4M | −$1.0M | −$111,356 |
| Net current asset value | $4.7M | $3.1M | $2.5M | $2.3M | $2.3M | $3.6M | $7.1M | $4.4M | −$1.0M | −$113,606 |
| Graham net-net per share | $6.57 | $3.73 | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | — | $1,661 | — | — | $0 | $0 | $0 | $0 | $0 |
| Capex / depreciation | 0.01 | 0.00 | 12,068.81 | 0.01 | 1.17 | 114.55 | 114.35 | 114.75 | 0.00 | 0.00 |
| Efficiency | ||||||||||
| Days payables outstanding | 292,431.9 | 114,169.1 | 122,875.2 | 1,697.1 | 3,096.3 | 271,466.5 | 93,632.2 | 143,197.0 | 116,959.6 | 18,571.7 |
| Receivables turnover | 0.00 | — | — | — | — | — | — | — | — | 0.00 |
| Payables turnover | 0.00 | 0.00 | 0.00 | 0.22 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $41,758 | — | — | — | — | — | — | — | — | $35,117 |
| Average payables | $452,668 | $176,728 | $189,868 | $281,301 | $467,466 | $419,472 | $144,938 | $220,876 | $181,047 | $28,748 |
| Intangibles / total assets | 0.0% | 0.1% | 0.1% | 4.4% | 3.3% | 0.1% | 0.1% | 0.1% | 21.1% | 5.2% |
Computed from ADIL's annual financial statements (latest annual report filed March 5, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ADIL valuation and financial ratios
Adial Pharmaceuticals earned a return on equity of −170.7% in fiscal 2025.
See the ADIL income statement, the ADIL chart for price history, or the ADIL stock overview for the latest quote and news.
ADIL key metrics FAQ
What is Adial Pharmaceuticals's return on equity?
Adial Pharmaceuticals's return on equity (ROE) was −170.7% in fiscal 2025: net income of -$8.0 million on average shareholders' equity of $4.7 million.
What is Adial Pharmaceuticals's free cash flow yield?
Adial Pharmaceuticals generated -$6.5 million of free cash flow in fiscal 2025, a free cash flow yield of −176.6% on its market value at year-end ($3.7 million).
What is Adial Pharmaceuticals's current ratio?
Adial Pharmaceuticals's current ratio was 4.42 at the end of fiscal 2025: current assets were 4.42 times current liabilities.